{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '126', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Authorship will be determined by mutual agreement and in line with International Committee', 'of Medical Journal Editors authorship requirements.', '10.1.6', 'Compliance with Study Registration and Results Posting Requirements', 'Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007', 'and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor', 'of the study is solely responsible for determining whether the study and its results are subject', 'to the requirements for submission to http://www.clinicaltrials.gov,', 'www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will', 'review this protocol and submit the information necessary to fulfill these requirements. MSD', 'entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.', 'Information posted will allow participants to identify potentially appropriate studies for their', 'disease conditions and pursue participation by calling a central contact number for further', 'information on appropriate study locations and study site contact information.', 'By signing this protocol, the investigator acknowledges that the statutory obligations under', 'FDAAA, the EMA clinical trials directive, or other locally mandated registries are that of the', 'Sponsor and agrees not to submit any information about this study or its results to those', 'registries.', '10.1.7', 'Compliance with Law, Audit, and Debarment', 'By signing this protocol, the investigator agrees to conduct the study in an efficient and', 'diligent manner and in conformance with this protocol; generally accepted standards of GCP', '(eg, International Conference on Harmonization of Technical Requirements for Registration', 'of Pharmaceuticals for Human Use GCP: Consolidated Guideline and other generally', 'accepted standards of GCP); and all applicable federal, state and local laws, rules and', 'regulations relating to the conduct of the clinical study.', 'The Code of Conduct, a collection of goals and considerations that govern the ethical and', 'scientific conduct of clinical investigations sponsored by MSD, is provided in this appendix', 'under the Code of Conduct for Clinical Studies.', 'The investigator agrees not to seek reimbursement from participants, their insurance', 'providers, or from government programs for procedures included as part of the study', 'reimbursed to the investigator by the Sponsor.', 'The investigator will promptly inform the Sponsor of any regulatory authority inspection', 'conducted for this study.', 'The investigator agrees to provide the Sponsor with relevant information from inspection', 'observations/findings to allow the Sponsor to assist in responding to any citations resulting', 'from regulatory authority inspection and will provide the Sponsor with a copy of the', 'proposed response for consultation before submission to the regulatory authority.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '127', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Persons debarred from conducting or working on clinical studies by any court or regulatory', \"authority will not be allowed to conduct or work on this Sponsor's studies. The investigator\", 'will immediately disclose in writing to the Sponsor if any person who is involved in', 'conducting the study is debarred or if any proceeding for debarment is pending or, to the best', \"of the investigator's knowledge, threatened.\", '10.1.8', 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic CRF unless', 'transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator', 'or qualified designee is responsible for verifying that data entries are accurate and correct by', 'physically or electronically signing the CRF.', 'Detailed information regarding Data Management procedures for this protocol will be', 'provided separately.', 'The investigator must maintain accurate documentation (source data) that supports the', 'information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review, and', 'regulatory agency inspections and provide direct access to source data documents.', 'Study documentation will be promptly and fully disclosed to the Sponsor by the investigator', 'upon request and also shall be made available at the study site upon request for inspection,', 'copying, review, and audit at reasonable times by representatives of the Sponsor or any', 'regulatory authorities. The investigator agrees to promptly take any reasonable steps that are', 'requested by the Sponsor or any regulatory authorities as a result of an audit or inspection to', 'cure deficiencies in the study documentation and worksheets/CRFs.', 'The Sponsor or designee is responsible for the data management of this study including', 'quality checking of the data.', 'Study monitors will perform ongoing source data review and verification to confirm that data', 'entered into the CRF by authorized site personnel are accurate, complete, and verifiable from', 'source documents; that the safety and rights of participants are being protected; and that the', 'study is being conducted in accordance with the currently approved protocol and any other', 'study agreements, ICH GCP, and all applicable regulatory requirements.', \"Records and documents, including participants' documented informed consent, pertaining to\", 'the conduct of this study must be retained by the investigator for 15 years after study', 'completion unless local regulations or institutional policies require a longer retention period.', 'No records may be destroyed during the retention period without the written approval of the', 'Sponsor. No records may be transferred to another location or party without written', 'notification to the Sponsor.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}